QURE · uniQure N.V. · Stock research

Current Thesis

Nothing new has come out of the company since the 2026-07-29 Q2 release, and that silence is now the structure. The stock closed $48.37 on 2026-08-21 against $48.62 on 2026-08-14, while RSI(14) unwound from 80.4 to 68.8 — The narrative leg on offer is unchanged in substance and shorter in duration: the FDA's 2026-06-17 Type B outcome accepted the three-year Phase I/II analysis against a propensity-matched Enroll-HD external control as the primary support for an accelerated-approval BLA, and the company reiterated on 2026-07-29 that the AMT-130 BLA and a UK MAA both land in Q3 2026. That window shuts 2026-09-30. Alongside it sits four-year topline safety and efficacy data on 24 Phase I/II patients (12 high dose, 12 low dose), cut at 2026-06-30 and guided to September. Both events are undated. Neither is the resolving gate, which is acceptance or refuse-to-file roughly 60 days after a submission that has not yet been announced.

Bullish and bearish views on uniQure N.V.

The model's bull view on uniQure N.V. (QURE), in brief: Digestion above the deal price. The 2026-06-24 offering cleared at $45.50; the 2026-07-17 close of $40.25 sat below it, and the 2026-08-21 close of $48.37 sits above it with the momentum reading cooled to 68.8. The July break of the deal price has been reclaimed and held for… The bear view: The news flow has stopped. No company press release between 2026-07-29 and 2026-08-22. The upgrade cycle that carried the move ran 2026-06-25 through 2026-07-29; nothing has replaced it, and the price has gone nowhere for a week. Costs are scaling ahead of an approval that does… Both cases follow in full.

Bull Case

• Digestion above the deal price. The 2026-06-24 offering cleared at $45.50; the 2026-07-17 close of $40.25 sat below it, and the 2026-08-21 close of $48.37 sits above it with the momentum reading cooled to 68.8. The July break of the deal price has been reclaimed and held for over a month.
• Funded well past the decision. Cash, cash equivalents and current investment securities of $810.3M at 2026-06-30 versus $622.5M at 2025-12-31, with operating expenses funded into 2030 (Q2 release, 2026-07-29). No financing is forced by the filing timeline.
• Confirmatory design trending cheaper. The 2026-06-17 release and the 2026-07-29 update both describe FDA considering a concurrent standard-of-care control instead of the sham surgical procedure it strongly recommended after the 2026-01-30 Type A meeting. Sham neurosurgery is the binding enrollment constraint in Huntington's.
• Sell-side sits above spot. Compilations dated 2026-08-12 put the brokerage consensus target at $65 against the 2026-08-21 close of $48.37; Wolfe Research upgraded to Outperform with a $65 target on 2026-07-29, modelling ~70% approval probability and $2B peak US AMT-130 sales versus a market it argued was pricing under 50%. HC Wainwright carried $80 (2026-06-29) and Mizuho $68 (2026-06-25).
• Efficacy anchor is intact. The June-2025 pivotal readout showed 75% slowing of progression on cUHDRS at 36 months at the high dose versus the external control. There is no approved disease-modifying therapy in Huntington's.
• Second asset is printing. AMT-260 six-month data disclosed 2026-06-22: 3 of 6 low-dose patients with 79–100% seizure reduction, no treatment-related serious adverse events; second-cohort enrollment guided complete in Q3 2026.

Bear Case

• The news flow has stopped. No company press release between 2026-07-29 and 2026-08-22. The upgrade cycle that carried the move ran 2026-06-25 through 2026-07-29; nothing has replaced it, and the price has gone nowhere for a week.
• Costs are scaling ahead of an approval that does not exist. Q2 2026 net loss $81.1M ($1.22 per share) versus $37.7M in Q2 2025; SG&A $17.4M, up $3.9M YoY, explicitly on staff added for an anticipated commercial launch; R&D $34.0M, down $1.4M.
• Revenue is not in the valuation. Q2 2026 revenue $5.8M versus $5.3M a year earlier. Market capitalisation was roughly $3.15B on 2026-08-07 per a DirectorsTalk compilation. The equity is an approval probability.
• A target was cut inside the run. Analyst-activity compilations record Barclays trimming to $60 from $65 on 2026-07-30 while keeping a positive rating — the first target reduction since the reversal, against a wide dispersion of published targets.
• The confirmatory control arm was still unagreed at the last update. FDA sought alignment on the design prior to BLA submission (2026-06-17); the 2026-07-29 update still described discussions as ongoing. An unresolved design point immediately upstream of a filing is a schedule risk on the filing.
• Issuance has followed every strength leg. A $150M offering announced 2026-06-22 was upsized and priced at $225M two days later, and a Form 4 records a CEO sale dated 2026-07-02 into the same advance.
• The prior regime high is far away. The 2026-08-21 close is 31.5% below the $70.59 52-week high, which predates the 2026-03-02 rejection. The June reversal restored the path, not the multiple.

Setup & Price Structure

Up 100.0% over three months into the 2026-08-21 close of $48.37, then flat for a week while RSI(14) fell 80.4 → 68.8. The reference levels that matter are close together: $45.50 (2026-06-24 offering price) as the shelf the July drawdown broke and August reclaimed, and $40.25 (2026-07-17 close) as the pivot that defined the post-offering low. Above sits nothing but the $70.59 52-week high, 31.5% away, with no intervening structure from 2026.

The narrative is maturing. The attention burst is dated and behind — 2026-06-17 reversal, 2026-06-22/24 financing, target raises on 2026-06-25 and 2026-06-29, the Wolfe upgrade on 2026-07-29 — and the last three weeks have produced one target cut (2026-07-30), one maintained rating (Stifel, 2026-08-01), a consensus-target compilation (2026-08-12) and a retail-facing options-flow screener headline (2026-08-14). It still works: price holds the reclaimed deal price. What has moderated is the arrival of new information.

Crowding and positioning observables, stated as observables: coverage in the last two weeks is aggregator and options-flow content rather than primary news; the brokerage consensus target of $65 sits 34% above the last close, so the sell-side is not the marginal seller; insider activity in the window is a sale (CEO Form 4, 2026-07-02); the company has issued equity into strength twice in 2026; and there is no earnings print inside the next 30 days — Q2 was reported 2026-07-29 and Q3 falls in late October. Event risk here is regulatory and unscheduled, not calendar-anchored.

Catalyst Calendar (next 30 days)

• ~2026-09-30 (est.) — Close of the guided Q3 2026 window for the AMT-130 BLA submission to FDA under accelerated approval.
• ~2026-09-30 (est.) — Close of the guided Q3 2026 window for the UK MAA submission to MHRA, following the March 2026 pre-submission meeting.
• ~2026-09-30 (est.) — AMT-260 second-cohort enrollment completion, guided to Q3 2026 on 2026-07-29.
• ~2026-10-28 (est.) — Q3 2026 results and corporate update (outside 30 days; first scheduled forum to confirm submission status and the agreed confirmatory control arm).

Elapsed catalysts

• September 2026 (no date announced) — Four-year topline safety and efficacy from Phase I/II cohorts 1 and 2: 24 patients, 12 high dose, 12 low dose, data cut 2026-06-30. (passed 57d ago)

What Would Change Our Mind

The structure that has to hold is the reclaimed $45.50 shelf and the 2026-07-17 pivot close of $40.25 beneath it; a weekly close below $40 undercuts both and gives back the entire post-Q2 re-rating, which is the gradeable break. Separately, the thesis is time-bound in a way price alone will not show: if 2026-09-30 passes with no BLA submission press release, or the Q3 update replaces "Q3 2026" with later or undated language, the only near-term event is gone and the equity reverts to funding a burn that ran $81.1M in Q2. A September four-year update showing cUHDRS separation materially below the 36-month 75% figure, or a treatment-related serious adverse event in the 24-patient set, changes the underlying probability rather than the schedule. On the other side, a submission announcement inside the window resets the clock to the acceptance-or-refuse-to-file decision roughly 60 days later, and that is where the dispersion in published targets ($60 to $80) actually resolves.

Correlation Notes

• Regulatory-sentiment cohort, not an index trade: the 2026-06-22 Regenxbio reversal — FDA allowing a refile of a previously rejected gene therapy — landed in the same week as the AMT-130 U-turn, and the 2026-06-26 Capricor advisory-committee scheduling moved that name against the group. Shared factor is CBER stance on accelerated approval with non-standard controls.
• Idiosyncratic risk dominates beta: the 2026-03-02 and 2026-06-17 announcements each repriced the shares by a multiple of a normal session's range, independently of biotech indices. Any correlation to XBI-type baskets breaks on agency communication days.
• No commercial revenue line ties the equity to healthcare-sector fundamentals; the $5.8M of Q2 2026 revenue is service and collaboration income, so sector earnings revisions are not a transmission channel here.
• Financing sensitivity runs through biotech capital-markets conditions rather than rates directly: the company has priced two offerings in 2026 within days of positive news, so a closed follow-on window would change the funding calculus even with $810.3M on hand at 2026-06-30.